Pharmaceutical Pen Testing: What 21 CFR Part 11 and cGMP Require

21 CFR Part 11 and current Good Manufacturing Practice (cGMP) regulations do not use the words penetration testing. That absence leads some pharma compliance teams to treat security testing as a separate obligation from regulatory compliance, one that sits in the IT security program rather than the quality system. That separation is a mistake. The controls that Part 11 and cGMP require, specifically around electronic record integrity, audit trail protection, access control and system reliability, are exactly the controls that penetration testing is designed to validate. Understanding the connection is necessary for building a testing program that satisfies both security and regulatory objectives. The cost of failing on the regulatory side is documented: in 2013, Ranbaxy paid $500 million in the largest drug safety settlement of its kind after pleading guilty to federal charges that included cGMP violations and false statements to the FDA. 

What Part 11 and cGMP Require

21 CFR Part 11 requires that electronic records be trustworthy, reliable and equivalent to paper records in terms of integrity and authenticity. It requires audit trails that capture who did what and when, access controls that limit system use to authorized individuals and electronic signatures that are uniquely linked to the signer. None of these requirements are met by policy alone. They require technical controls that function correctly under adversarial conditions, not just under normal operating conditions. 

cGMP requirements, particularly as they apply to computer systems under 21 CFR Parts 211 and 212, require that computerized systems used in drug manufacturing are validated, that data generated by those systems is accurate and complete and that access to those systems is controlled and logged. The Food and Drug Administration's (FDA) data integrity guidance documents, while not regulations themselves, make clear that the agency expects these controls to be tested and verified, not just documented. 

The Systems That Require Testing

The systems in scope for compliance-driven pen testing in pharma are those that create, modify, maintain or transmit regulated electronic records. Manufacturing execution systems that generate electronic batch records. Laboratory information management systems (LIMS) that produce analytical data supporting release decisions. Enterprise resource planning (ERP) systems that manage regulated manufacturing documentation. Distributed control systems (DCS) and supervisory control and data acquisition (SCADA) systems that control and record process parameters in drug manufacturing. 

Cloud-hosted regulated systems require particular attention. The FDA's position on cloud hosting for GxP (good practice) systems is that the pharmaceutical company retains responsibility for data integrity and access control regardless of where the system is hosted. That means the pen test scope for a cloud-hosted LIMS needs to include the cloud environment configuration and the access controls governing who can reach the system from outside the corporate network. 

How to Test Without Violating Validated State

The central challenge of pen testing validated pharma systems is that the testing itself can constitute a change to the validated system. An active scan that modifies configuration, a test that writes to an audit trail or an exploitation attempt that alters system state may require revalidation before the system can be used for regulated activities. This is not a theoretical concern. Pharma companies have had to revalidate systems after security testing that was conducted without adequate planning.

The solution is a qualified test environment: a mirror of the production system built to the same specification and qualified through the same installation, operational and performance qualification (IQ, OQ, PQ) process. Active testing occurs in the test environment. Production systems receive only passive reconnaissance, which can be conducted without risk to validated state. The test environment findings are treated as representative of production, with documented justification for any differences between the two environments. 

What Your Report Must Demonstrate for Compliance

A pen test report that satisfies FDA compliance requirements for Part 11 and cGMP systems needs to demonstrate more than vulnerability findings. It needs to demonstrate that audit trail integrity was tested: that an attacker cannot modify or delete audit trail entries without detection. It needs to demonstrate that access controls were tested under adversarial conditions: that privilege escalation, credential theft and unauthorized access attempts were made and their outcomes documented. It needs to demonstrate that data integrity controls function correctly when the system is under attack, not just under normal operating conditions. 

The report should map each test category to the specific regulatory requirement it validates. That mapping is what allows the report to function as compliance evidence, not just as a security assessment. It is also what allows the quality team to use pen test findings in their risk management process rather than treating them as IT security findings that have no bearing on the quality system.

Preparing for Your Next FDA Inspection

FDA inspectors conducting data integrity inspections are increasingly asking about cybersecurity controls and how they are tested. An organization that can produce pen test reports demonstrating that audit trail integrity, access controls and electronic record protections were tested against adversarial scenarios is in a significantly stronger position than one that can only produce policy documentation and system validation records. 

Building that capability requires aligning the pen test program with the quality system, not running it as a parallel IT security activity. That alignment starts with scoping that reflects regulatory requirements, extends through a testing methodology that validates the controls regulators care about and ends with reporting that speaks the language of compliance, not just security. 

Your next inspection will ask how your controls were tested, not just how they were documented. Request a compliance-aligned scoping session and build a pen test program your quality team can stand behind.